Assembly Biosciences (ASMB) Projected to Post Quarterly Earnings on Thursday

Key Points

• Q1 2026 results due after market close on May 7: Analysts expect a loss of ($0.73) per share and revenue of $9.266 million, with an earnings call scheduled for May 6 at 4:00 PM ET.
• In the prior quarter Assembly reported a surprise $2.48 EPS and $42.47 million in revenue—well above estimates—but the company still recorded a negative net margin and ROE, and analysts forecast roughly -$1 EPS this fiscal year and -$2 next year.
• Brokerage coverage is mixed but tilting positive: five Buys, one Hold and one Sell with an average rating of Moderate Buy and an average price target of $42.75; the stock trades around $26.33 with a market cap near $418 million.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) is expected to be issuing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $9.2660 million for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:00 PM ET.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The firm had revenue of $42.47 million during the quarter, compared to analysts' expectations of $7.42 million. On average, analysts expect Assembly Biosciences to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Assembly Biosciences Trading Down 2.5%

ASMB stock opened at $26.33 on Thursday. Assembly Biosciences has a 12 month low of $11.20 and a 12 month high of $39.71. The company has a 50-day moving average price of $28.58 and a 200 day moving average price of $30.51. The stock has a market cap of $418.38 million, a PE ratio of -35.58 and a beta of 1.15.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASMB. Bank of America Corp DE lifted its holdings in Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 3,319 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock valued at $219,000 after buying an additional 6,823 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new stake in Assembly Biosciences during the 4th quarter valued at about $228,000. Virtus Investment Advisers LLC bought a new stake in Assembly Biosciences during the 4th quarter valued at about $251,000. Finally, Qube Research & Technologies Ltd bought a new stake in Assembly Biosciences during the 3rd quarter valued at about $282,000. Institutional investors own 19.92% of the company's stock.

Wall Street Analysts Forecast Growth

ASMB has been the subject of a number of recent analyst reports. Guggenheim lifted their price target on shares of Assembly Biosciences from $39.00 to $43.00 and gave the stock a "buy" rating in a research note on Monday, April 6th. Wall Street Zen raised shares of Assembly Biosciences from a "buy" rating to a "strong-buy" rating in a research note on Sunday, March 29th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Assembly Biosciences in a research note on Monday, April 20th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Assembly Biosciences in a research note on Thursday, March 26th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $42.75.

About Assembly Biosciences

Assembly Biosciences, Inc NASDAQ: ASMB is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company's core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly's research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company's lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.